An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis

Research output: Contribution to journalArticle

Abstract

Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare, progressive, fatal multi-systemic disease, autosomal dominantly inherited with heterogeneous clinical phenotype caused by mutations in the TTR gene. Mutations promoting proteolytic remodeling and tetramer dissociation result in fragmented and full-length TTR monomers that misfold, aggregate and deposit at multiple sites (mainly nerves and heart) causing peripheral neuropathy and/or cardiomyopathy. Areas covered: The authors discuss patisiran, the first approved RNA interference-based therapeutic agent that suppresses the circulating levels of the amyloidogenic protein TTR both wild-type and mutant. This compound demonstrated a safe clinical profile in phase I and II studies and showed a significant clinical effect in a phase III (APOLLO) trial in ATTRv patients. An open-label-extension study is still underway but, based on the positive results, the regulatory agencies granted approval for the treatment of ATTRv with polyneuropathy in Stage I and II. Expert opinion: The patisiran program has demonstrated that substantial TTR concentration reduction is associated with significant and sustained improvement in polyneuropathy scores, quality-of-life profile and several outcome measures that capture the systemic burden of the disease. The drug resulted safe also in long term follow-up studies while its efficacy for ATTR with cardiomyopathy is under investigation.

Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Polyneuropathies
Cardiomyopathies
Amyloidogenic Proteins
Mutation
Expert Testimony
Peripheral Nervous System Diseases
RNA Interference
Quality of Life
Outcome Assessment (Health Care)
Phenotype
Therapeutics
Pharmaceutical Preparations
Genes
patisiran
Amyloidosis, Hereditary, Transthyretin-Related

Keywords

  • cardiomiopathy
  • hereditary transthyretin mediated amyloidosis
  • Patisiran
  • peripheral neuropathy
  • RNA interference

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{07d2563c42894b27bdceca6e86a6d8db,
title = "An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis",
abstract = "Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare, progressive, fatal multi-systemic disease, autosomal dominantly inherited with heterogeneous clinical phenotype caused by mutations in the TTR gene. Mutations promoting proteolytic remodeling and tetramer dissociation result in fragmented and full-length TTR monomers that misfold, aggregate and deposit at multiple sites (mainly nerves and heart) causing peripheral neuropathy and/or cardiomyopathy. Areas covered: The authors discuss patisiran, the first approved RNA interference-based therapeutic agent that suppresses the circulating levels of the amyloidogenic protein TTR both wild-type and mutant. This compound demonstrated a safe clinical profile in phase I and II studies and showed a significant clinical effect in a phase III (APOLLO) trial in ATTRv patients. An open-label-extension study is still underway but, based on the positive results, the regulatory agencies granted approval for the treatment of ATTRv with polyneuropathy in Stage I and II. Expert opinion: The patisiran program has demonstrated that substantial TTR concentration reduction is associated with significant and sustained improvement in polyneuropathy scores, quality-of-life profile and several outcome measures that capture the systemic burden of the disease. The drug resulted safe also in long term follow-up studies while its efficacy for ATTR with cardiomyopathy is under investigation.",
keywords = "cardiomiopathy, hereditary transthyretin mediated amyloidosis, Patisiran, peripheral neuropathy, RNA interference",
author = "Paolo Milani and Roberta Mussinelli and Stefano Perlini and Giovanni Palladini and Laura Obici",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14656566.2019.1671352",
language = "English",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - An evaluation of patisiran

T2 - a viable treatment option for transthyretin-related hereditary amyloidosis

AU - Milani, Paolo

AU - Mussinelli, Roberta

AU - Perlini, Stefano

AU - Palladini, Giovanni

AU - Obici, Laura

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare, progressive, fatal multi-systemic disease, autosomal dominantly inherited with heterogeneous clinical phenotype caused by mutations in the TTR gene. Mutations promoting proteolytic remodeling and tetramer dissociation result in fragmented and full-length TTR monomers that misfold, aggregate and deposit at multiple sites (mainly nerves and heart) causing peripheral neuropathy and/or cardiomyopathy. Areas covered: The authors discuss patisiran, the first approved RNA interference-based therapeutic agent that suppresses the circulating levels of the amyloidogenic protein TTR both wild-type and mutant. This compound demonstrated a safe clinical profile in phase I and II studies and showed a significant clinical effect in a phase III (APOLLO) trial in ATTRv patients. An open-label-extension study is still underway but, based on the positive results, the regulatory agencies granted approval for the treatment of ATTRv with polyneuropathy in Stage I and II. Expert opinion: The patisiran program has demonstrated that substantial TTR concentration reduction is associated with significant and sustained improvement in polyneuropathy scores, quality-of-life profile and several outcome measures that capture the systemic burden of the disease. The drug resulted safe also in long term follow-up studies while its efficacy for ATTR with cardiomyopathy is under investigation.

AB - Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare, progressive, fatal multi-systemic disease, autosomal dominantly inherited with heterogeneous clinical phenotype caused by mutations in the TTR gene. Mutations promoting proteolytic remodeling and tetramer dissociation result in fragmented and full-length TTR monomers that misfold, aggregate and deposit at multiple sites (mainly nerves and heart) causing peripheral neuropathy and/or cardiomyopathy. Areas covered: The authors discuss patisiran, the first approved RNA interference-based therapeutic agent that suppresses the circulating levels of the amyloidogenic protein TTR both wild-type and mutant. This compound demonstrated a safe clinical profile in phase I and II studies and showed a significant clinical effect in a phase III (APOLLO) trial in ATTRv patients. An open-label-extension study is still underway but, based on the positive results, the regulatory agencies granted approval for the treatment of ATTRv with polyneuropathy in Stage I and II. Expert opinion: The patisiran program has demonstrated that substantial TTR concentration reduction is associated with significant and sustained improvement in polyneuropathy scores, quality-of-life profile and several outcome measures that capture the systemic burden of the disease. The drug resulted safe also in long term follow-up studies while its efficacy for ATTR with cardiomyopathy is under investigation.

KW - cardiomiopathy

KW - hereditary transthyretin mediated amyloidosis

KW - Patisiran

KW - peripheral neuropathy

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=85074001507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074001507&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1671352

DO - 10.1080/14656566.2019.1671352

M3 - Article

C2 - 31566422

AN - SCOPUS:85074001507

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

ER -